Member Info for T0n1c

"SYME also confirms that it will be issuing a Trading Update to the market before the end of this month."

BEFORE the end of this month.

Gregg, maybe you can think about us NOT getting a stonking RNS here in ODX.. see how that plays out?

I don't know the process of commissioning kit well enough to argue.
My assumptions are that the numbers in the chart are the total number available at the end of the month and that there is no ramp up through the course of that same month.
Maybe there are others on here that know the process, or we wait to be told, or we just take my figures as worst case estimate, yours as best case.
Either way, from the messaging in RNS and in response to investors questions, I, personally, still think Omega have been producing tests (likely ABC-19) in the millions in readiness for, to use Abingdons words, "significant sizeable orders, ahead of the end of Abingdon Health's financial year" (June).

So back of a fag packet numbers, (hoping the formatting works on this).... assuming the increase in the capacity chart shared in the investor presentations is effective from month end.
https://webcasting.brrmedia.co.uk/broadcast/5fbf9d78b19325729a9d7d05/5fc522050c7aa22257c26c99
These were allocated numbers, so there is no reason ABC-19 tests couldn't be produced in the 'other' capacity also.
And given we've seen ABC-19 tests with date stamps of November, I've based calculations from November.

ABC-19 production weeks total
November 200000 4 800,000
December 200,000 4 800,000
January 200,000 3 600,000
February 200,000 4 800,000
March 200,000 1 200,000
Total allocated ABC-19 - 3,200,000
Other
November 0 4 0
December 50,000 4 200,000
January 300,000 3 900,000
February 400,000 4 1,600,000
March 700,000 1 700,000
Total - Other - 3,400,000

Grand Total - 6,600,000
October production was max 800,000 total.

I would assume also, that some capacity is needed for the Tech Transfer exercises. So Mologic, and perhaps the AVCT tie up (still TBC), may be using some of the above capacity too.
So from November to now, I'd suggest we could have had nearer to 5-6m tests usable capacity rather than 12m stated above.
Happy to be corrected on this, as I am by no means a diagnostics, nor manufacturing, expert.
And yeah, I think a lot of that will have been used to proceed ABC-19, and CD4.
I'll agree the Visitect triple AB is an unknown, until we are told more.

@Twatcher... again;

In a previous RNS, ABDX state;
"The Company is continuing to manufacture the AbC-19TM Rapid Test in anticipation of additional orders and to that end Abingdon's regulatory department is currently working with UK-RTC partners on regulatory approval in a total of 27 territories. " @Tue, 26th Jan 2021 07:01

Colin recently responded to an investor with;
"We are currently building UK-RTC stock for forecasted demand, CD4 tests and transferring Mologic antigen test"

Todays Abingdon RNS;
"Over recent weeks, there has been growing evidence that rapid antibody testing can be used to determine an individual's antibody status both prior to and after vaccination, a crucial factor in stratifying patients and determining resource allocation on overburdened health systems. As a result of this, and the leading accuracy of Abingdon Health's test, the Company anticipates an increased demand for rapid antibody tests that can be used as a companion to COVID-19 vaccines."

"The Company is making good progress in the approval of AbC-19™ for testing in the US as well as with over 30 other countries worldwide."

"In the current financial year, the key driver of the Company's financial performance will be the predicted roll-out of antibody testing in the territories that Abingdon Health is targeting and the sales of its AbC-19™ COVID-19 rapid test. Abingdon Health has a growing pipeline of international opportunities, with seven countries now identified as Tier 1 commercial targets which have potential to deliver significant order volume in this financial year"
*Financial year end is 30th June

Given that both companies are continuing to manufacture the tests.
Given the phrasing of "initial order" from the UK gov
Given the active promotion of the test being available from Abingdon and CIGA
Given the recent results from independent studies
Given the latest statements in the Abingdon Interim results...
I think it's likely, and I trust and believe, they are both manufacturing ABC-19 tests until an AG test is selected by the DHSC.
It's up to to you what you want think/trust.

DYOR, GLA.

Something along the lines of, "We've invested heavily in the UK diagnostics sector, and are proud to announce that a working amongst numerous UK companies has resulted in the next generation of LFT. These tests are easier to administer and are more reliable in the results they present. We have secured UK manufacturing capacity, at scale, and efforts are already underway to mass produce the millions of tests needed to see us out of Covid"... wouldn't go amiss.

Bit of a pain that money is locked in, but at least it's not going down.

"the Company expects to have delivered on Captive-Funding and Self-Funding initiatives by the end of the first quarter of 2021."

There's only s couple of weeks before Q1 concludes... Happy to wait a couple more weeks for a nice RNS confirming the above, just as suspension is lifted.

With the £8b tender on Bidstat, followed by a weekend of press of testing our way out of lockdown.
Innova making noise in the press.
BBC putting LFT testing down
Martin Lewis putting LFT testing down
School testing commencing, huge demand increase

I wonder if this is the week that "the" DHSC test is announced, better than all other tests used to date (except perhaps SureScreen).

Calm down Dan... nobody is asking you to trust or believe Big Jock, or indeed any other member on this board.
That is entirely your decision to make.

Big Jock, nice to see pics of your visit there today.
Some good times ahead.. and soon.

GLA

Velatastic - "Some tool on twitter predicting £2- £5."

Who's the tool? Someone who's done their homework and believes in their investment, or someone who is staying invested because it was a higher SP previous and therefore feels owed?

Yes, there are a lot of unknowns, but there are a lot of pieces to put together that lend themselves to an easy £2+ SP.

"Hugely concerned is an understatement with £25k on the line here!"
you would appear to be in profit (29510 @ £25k).... If you're so concerned, sell and move on to something you're more comfortable with.

2-5mins according to the website Matt;
https://www.vatic.health/how-it-works

I was wondering about the Vatic test.
Currently being trialled in Edinburgh Airport
https://www.med-technews.com/news/Covid-19-Medtech-News/edinburgh-airport-rapid-covid-19-testing-trial-to-determine-/
"PocDoc and BioSure are running the trial, delivering an end-to-end testing solution using the Vatic KnowNow saliva antigen test. "
https://www.biosure.co.uk/tests/covid-19-antigen-test/

Really sorry for your loss DJ. My condolences.

Agreed.. not massive capacity... not even huge capacity.. I'd go as far as to suggest we probably did it for free... maybe we even paid them to use our test (doubt it)... that's not the point.

The test was used as a benchmark.. That shows me the test is bloody good.

It's a home service MHRA approved Antibody test, competitively priced by Screen4, and I'm sure Omega will be seeing good price/margin on these.
As I say, a nice surprise about the agreement and nice to see Screen4 actively promoting it.
I think may even surprise more in time to come when we see figures.

https://wellcomeopenresearch.org/articles/6-18/v1
All samples were screened by ELISA for the detection of anti-SARS-CoV-2 IgG (Omega Diagnostics, Alva, UK), as per the manufacturer’s instructions.

With regard to the Screen4 agreement... and Omega ELISA capacity...

In June, as part of the placing, we were told there were plans to expand ELISA testing to 1m tests per week.
Now that was before it became a Lab service, which I imagine is now the limit on capacity now, but we could easily be above 46k per week.
It's the 'first' supplier agreement.
We've already seen the test was used in validating LFTs too, so who knows where else it's being used.

This one for me was a nice surprise.
As with all these things, it seems... time will tell how popular the test is.

I just got the very same email.

All the non-invested come out and regale of how they sold at the top, and revel in trying to find holes and pick pick picking away. Well done chaps and chapesses. Have a good day.

IMO a very good RNS. One we were not expecting, which are (when positive as this one is) is always a nice surprise.
We now know there is appetite for the ELISA test, which is great.
£52 price point is reasonable, compared to other lab based tests.
£52 would also indicate a very reasonable ODX price/margin point too. Hopefully we'll hear more on that in due course.

In the meantime the ABC-19 test is selling to non-UK gov suppliers, which means more profit for ODX. Manufacture dates are November 2020, and in addition to Colins recent comment that ODX have been producing ABC-19 tests, during the LFT expansion and whilst TT on Antigen progresses, in anticipation of orders, this looks to be paying off.
ABC-19 MHRA approval pending.
ABC-19 US Trademark & FDA approval progressing.
27 countries reviewing the ABC-19 test.
The Mologic AG TT (if not already completed, pending UK Gov announcement) must be near completion.
UK Gov AG contract updates - Order info pending.
CD4 sales update pending (my get that in year end update I guess)
China Food Intolerance, and break into US too... update due (as above)
There's a whole lot more to come here.

Interesting point for me, and I'll throw this one for the non-invested... we've seen Visitect triple AB tests for sale with 3rd party sellers, so why no (non, to satisfy TWATcher) RNS for those I wonder?

Have a good day all.

https://screen4.org/product/finger-prick-antibody-test/